Clinical Trial Update: T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating a T-cell therapy in combination with nivolumab, relatlimab, and ipilimumab in metastatic ovarian cancer and related peritoneal canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Relatlimab (relatlimab)
• T-cell therapy (unspecified)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Inge Marie Svane | Conditions: Metastatic Ovarian Cancer, Metastatic Fallopian Tube Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-08-12